Top Banner
Basics of Immuno-Oncology 2016. 6. 25 Kyong Hwa Park MD, PhD Oncology/Hematology Korea University Hospital
91

Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Aug 03, 2020

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Basics of Immuno-Oncology

2016. 6. 25

Kyong Hwa Park MD, PhD

Oncology/Hematology

Korea University Hospital

Page 2: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Contents

• Immune microenvironment in cancer

• Immunologic therapeutics in Oncology

- Cytokines

- Vaccines

- Immune checkpoint Inhibitors – a new breakthrough

- Cell-based treatment

• Rational Application of Immunotherapeutics - Biomarkers

- Combination strategy

- Immune monitoring

• Summary & Future directions

Page 3: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Coley’s Toxins

• William Coley (New York surgeon) began intratumoral injections of live or inactivated bacteria (1891)

• Stimulate antibacterial phagocytes that might kill bystander tumour cells

Nature Reviews Cancer 9, 361-371 (May 2009)

Page 4: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Science 25 March 2011

Page 5: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Cellular Immunity in Tumor microenvironment

Mast cells

T cells N1 neutrophils

M1 macrophage

NK cells

B cells

Page 6: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Chronic Inflammation directs Th2 Immunity

Primary tumor-derived factors

Successful metastatic outgrowth

Immune-mediated dormancy/Elimination

Cancer Res October 1, 2013 73; 5852

Page 7: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

CD4+ Treg Immune Regulation

Front. Immunol., 18 November 2013

Targeting DCs

Metabolic disruption

Competition

Cytolysis of Teff Inhibitory cytokines

Page 8: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Tumor Reprogramed Myeloid Cells

Nature Reviews Immunology 12, 253-268

Page 9: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Immune Contexture

Page 10: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Pages et al, NEJM, 2005

Immunity can Impact Disease Outcome: Role of Th1 CD4+ T Cells

Galon et al, Science, 2006

Factors Predicting Outcome:

Th1 TEM

Central Dense

>400 samples

75 samples

Th1 Signature: IFN

J Galon et al, Science 2006

Page 11: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Type, Density, and Location of Immune Cells

J Galon et al, Science 2006

Page 12: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Association of Immune Cell Infiltration and Prognosis

Fridman WH et al, Nat Rev Cancer 2012

Page 13: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

다음 중 직접 암세포 살상 기능이 알려진 면역세포는?

1) Naïve T cell

2) Dendritic cells

3) Foxp3+ CD4 T cells

4) CD8+ T cells

5) CD19+ B cells

Page 14: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Cancer Immunity Cycle

Immunity 39, July 25, 2013

Page 15: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Stimulatory vs Inhibitory Factors in Cancer Immunity Cycle

Immunity 39, July 25, 2013

Page 16: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS
Page 17: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

How to harness immune system to treat cancer?

- Make TME ‘Inflamed’

Page 18: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Therapeutic Strategies to Harness Immune System

Page 19: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Effect of Anti-cancer Treatment on Immune Cells

Trends in Immunology April 2015, Vol. 36, No. 4, 2015

Indirect Effects Direct Effects

Page 20: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Malignant Melanoma

Page 21: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Role of RT in Induction of the Antitumor Immune Response

2013, JCI

Page 22: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Abscopal Effect by Radiotherapy

N Engl J Med 2012;366:925-31

Page 23: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

M/62, mRCC

• Rt RCC – Radical nephrectomy, clear cell type

• 5년 후 Recur: 1L Bevacizumab/IFNg 임상참여

• 2L Sunitinib: PD

• General condition and organ function - fair

Page 24: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

What’s your next treatment in Korea?

1) Everolimus

2) Pazopanib

3) Axitinib

4) High dose IL-2

5) Nivolumab

Page 25: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Cytokine therapy: HD IL-2

Clin Cancer Res; 21(3) February 1, 2015

Page 26: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Durable response & Life Prolongation

Clin Cancer Res; 21(3) February 1, 2015

Page 27: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Cancer Vaccines

Educating APCs properly

Page 28: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

GVAX Probably Improves PDA Patients

• GVAX: a human whole cell granulocyte macrophage colony-stimulating factor (GM-CSF) secreting pancreatic cancer vaccine

• Phase II Study in patients received CCRT after R0/R1 resection for PDA

Ann Surg Oncol. 2013 Dec; 20(0 3): S725–S730.

Page 29: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Combination Strategy: GVAX + PD-1/PD-L1 Ab

J Immunother. 2015 Jan;38(1):1-11

Patients

Mouse CD8+IFNɣ+ (Spleen, TIL) IFNɣ+ (Spleen, TIL)

Page 30: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Personalized Immunotherapy based on Tumor Neoantigen

Schreiber et al, JCI Aug 2015

Neoantigen-specific and self-antigen–specific T cells? Proteosomal processing? Correct identification of CD4 epitopes? In vitro detection of Ag processing and presentation?

Page 31: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Dendritic Cell in Cancer Immunotherapy

Nature Medicine 6, 966 - 968 (2000)

Page 32: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

DC Therapy for CRPC Study 1 Study 2

Provenge (n=341) Control (n=171) Provenge (n=82) Control (n=45)

mOS (m) 25.8 21.7 25.9 21.4

HR (95%CI) 0.775 (0.614, 0.979) 0.586 (0.388, 0.884)

p-value 0.032 0.010

www.dendreon.com

US FDA Approval! April 2010

Page 33: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Intervention Based on Tumor Burden

1:10,000 T cells >1:10,000 T cells >1:100 T cells?

Vaccine Prevention

Therapeutic Vaccines

Alternative Strategies

Dis

eas

e B

urd

en

Vaccines Adoptive Cell Therapy

No Disease Microscopic Disease Established Disease

Page 34: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

52세 여자가 우측 발뒤꿈치에 생긴 점을 주소로 내원하여 악성 흑색종 광

범위 절제 및 서혜부 감시 림프절 생검술 및 절제 후 3기암 (BRAF mutant)

으로 진단되었다.

향후 환자의 경과를 호전시키기 위해 적용할 수 있는 가장 적절한 면역학

적 치료법은?

1) Nivolumab

2) CAR-T cell therapy

3) Vemurafenib

4) High dose IL-2

5) Cancer vaccine

Page 35: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Immune checkpoint Inhibitors – a new Breakthrough

Page 36: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS
Page 37: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Priming phase Effector phase

CTLA-4

PD-L1

NEJM 366;26 2518 June 28, 2012

Page 38: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

History of anti-CTLA Antibody

AACR Cancer Progress Report 2014

Page 39: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100

OS Ipilimumab/gp100 (n=403)

Ipilimumab (n=137)

Gp100 (n=136)

mOS (mon) 10.0 10.1 6.4

vs gp100 HR 0.68 (0.55–0.85) 0.66 (0.51–0.87)

P <0.001 0.003

vs Ipilim HR 1.04 (0.83–1.30)

P 0.76

ORR 5.7 % 11.0 %

N Engl J Med 363;8 august 19, 2010

US FDA Approval in March 2011 KFDA Approval in Dec 2014

Page 40: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Mechanisms of PD-1 Expression

Nature Immunology 14, 1212–1218 (2013)

Page 41: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

CD8+T cell Dynamics in Infection

Trends in Immunology April 2015, Vol. 36, No. 4

Acute Ag/functional memory Chronic Ag/ Exhaustion

Page 42: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

PD-1/PD-L1: Exhaustion of T cells

1) Antagonizing TCR signaling

2) Decreased survival, proliferation, altered metabolism

3) Reduced proliferation via RAS path

4) Altered transcription

5) Altered T cell motility

Trends in Immunology April 2015, Vol. 36, No. 4

Page 43: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

PD-1 and T cell Dysfunction

Jan, 2015, Nature Rev Immunology

Page 44: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Expression of PD-L 1 in Tumors

Cancer types % PD L-1(+) Cancer types % PD L-1(+)

Melanoma 40-100 Ovarian cancer 33-80

NSCLC 35-95 Gastric carcinoma 42

Nasopharyngeal ca 68-100 Esophageal ca 42

Glioblastoma/ mixed glioma

100 Pancreatic cancer 39

Colon 53 RCC 15-24

HCC 45-93 Breast cancer 31-34

Urothelial cancer 28-100 Lymphomas 17-94*

Multiple myeloma 93 Leukemias 11-42

Chen DS, Clin Cancer Res October 19, 2012.

Page 45: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Phase I Study of Single-Agent Anti–PD-1 in Refractory Solid Tumors

• MDX-1106 (BMS-936558/ONO-4538)

: fully human IgG4 mAb specific for humanPD-1

• Patients (n=39): CRC(14), Melanoma(10), NSCLC(8), Prostate(6), RCC(1)

Dose (mg/kg) No. of patients

Total No. of Doses Best Response (Duration in month) 1 2 3 5 11

0.3 6 6 0 0 0 0 N/A

1 6 3 1 1 1 0 1 MXR (1)

3 6 3 0 2 1 0 1 CR (21+)

10 21 15 1 4 0 1 2 PR(3+, 16+), 1MXR (1)

Total 39 27 2 7 2 1 1 CR, 2 PR, 2 MXR

Brahmer JR, J Clin Oncol 28:3167-3175. 2010

Page 46: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Expanded Phase I Study

Dose of anti-PD-1 Ab

Objective response

ORR Duration of

response Stable disease ≥

24wk PFS rate at

24 wk

Melanoma

NEJM June 28, 2012

Page 47: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Dose of anti-PD-1 Ab

Objective response

ORR Duration of

response (M) Stable disease ≥

24wk PFS rate at

24 wk

NSCLC

NEJM June 28, 2012

Page 48: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

NK Cells: Selected clinical trials with expanded allogeneic NK cells

Front. Immunol., 03 June 2015

Page 49: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Phase I : Random Healthy Donor–Derived Allo-NK Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

• Maximum dose (3 × 107 cells/kg, triple infusion): tolerable without significant AE

• Of 17 evaluable patients, 8 patients (47.1%) SD, 9 (52.9%) PD.

Cancer Immunol Res March 2016 4; 215

Treg TGFβ1

MDSC

Page 50: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Adoptive T cell Therapy • Genetically engineered TCR expressing T cells

2006 Science

Page 51: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Genetically engineered T-cell receptor recognizing NY-ESO-1 in Synovial Sarcoma

• T cells transduced with a retrovirus encoding a TCR against an HLA-A*0201 restricted NY-ESO-1 epitope

Clinical Cancer Research, 21 (2015)

Synovial sarcoma (n=18) Melanoma (n=20)

Page 52: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

CAR T-Cell Therapy

: Chimeric Antigen-Receptor based Therapy

52 Clin Cancer Res; 18(10) May 15, 2012

Page 53: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

CAR T-Cell Therapy

: Engineering Patients’ Immune Cells to Treat Their Cancers

53

Clin Cancer Res; 18(10) May 15, 2012

Page 54: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

CAR-T cell Therapy in ALL

N Engl J Med 2014; 371:1507-1517

Page 55: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

CAR-T cells Immunotherapy in Solid Cancers

• Target antigen?

• T cell expansion protocol

• Appropriate cell dose

• Patient conditioning

• Monitoring

• Elimination of CART

2016 AAAS, Riddell et al

Page 56: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Metastatic Cancer Remission

• Patient selection ?

• Anti-tumor immune response? • How long treat? • Combination approach?

• Still immune response? • Retreat?

Clinical Questions that you might have….

PD-1 blockade

Page 57: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Usual Pattern of Clinical Response

Progressive Disease - 왜 반응이 없는가? - 항종양 면역 반응의 부재

Stable Disease - 더 효과를 높일 방법은 없는가? - Immune signal 증폭 방법은?

Durable responses - 완전 관해를 이루는 방법은? - 면역 반응유지를 모니터 할 방법은?

Page 58: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Rational Application of Immunotherapeutics

• Biomarkers

- PD-1/PD-L1 expression

- Mutational load

• Combination strategy

• Immune monitoring

Page 59: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

MPDL3280A (anti-PD-L1) in Urothelial Cell Cancer

Nature, 2014 Nov

Page 60: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

PD-L1 Expression on TILs

Nature, 2014 Nov

Page 61: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

• PD-L1 expression status by IHC: anti–PD-L1 antibody clone 22C3 (Merck)

• Cells counted: neoplastic and intercalated mononuclear inflammatory cells

KEYNOTE-001: Phase Ib study of Pembrolizumab for the Treatment of NSCLC

N Engl J Med 2015;372:2018-28.

Page 62: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

PFS OS All patients

Prev Tx

No Prev Tx

All patients

Prev Tx

No Prev Tx

N Engl J Med 2015;372:2018-28.

Page 63: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Randomised, phase 3 study of Nivolumab vs Docetaxel in advanced Squamous NSCLC

after one prior Platinum-containing regimen

Stage IIIB or IV squamous-cell NSCLC who had disease recurrence after one prior platinum-containing regimen

Nivolumab 3 mg/kg q 2 wks

Docetaxel 75mg/㎡ q 3wks

R 1:1

Stratification: Prior use of paclitaxel therapy (yes vs. no)

Geographic region

(United States or Canada vs.Europe vs. rest of the world

[Argentina, Australia, Chile, Mexico, and Peru]). Primary endpoint: Overall survival

N=272

N Engl J Med 2015;373:123-35.

Page 64: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

N Engl J Med 2015;373:123-35.

9.2 mon vs 6.0 mon

3.5 mon vs 2.8 mon

Page 65: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

N Engl J Med 2015;373:123-35.

• Percent membranous staining in ≥100 tumor cells. • Archival or recent biopsy • (Dako North America) used a rabbit monoclonal antihuman

PD-L1 antibody (clone 28–8, Epitomics).

Page 66: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Randomised, phase 3 study of Nivolumab vs Docetaxel in advanced non-Squamous NSCLC

after one prior Platinum-containing regimen

Stage IIIB or IV nonsquamous-cell NSCLC who had progressed during or after platinum-based chemotherapy

Nivolumab 3 mg/kg q 2 wks

Docetaxel 75mg/㎡ q 3wks

R 1:1

• Stratification: Prior maintenance treatment (yes vs. no)

Line of therapy (second line vs. third line).

• Primary endpoint: Overall survival

N=582

N Engl J Med SEP2015; DOI: 10.1056/NEJMoa1507643

Page 67: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

N Engl J Med SEP2015; DOI: 10.1056/NEJMoa1507643

12.2 mon vs 9.4 mon

2.3 mon vs 4.2 mon

Page 68: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

PD-L1 expression predicts Survival

N Engl J Med SEP2015; DOI: 10.1056/NEJMoa1507643

Page 69: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

PD-L1 as a Biomarker?: Issues

• Tumor heterogeneity

• Interval between biopsy and treatment

• Primary vs metastatic disease

• Ab and staining conditions

• Defining a positive result (cut-offs)

- Immune cells vs tumor cells

- Location of expression: intracellular vs surface vs stroma

- Intensity, percent of positive cells

- Distribution

Page 70: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Estimate of the Neoantigen Repertoire in Human Cancer.

Science 3 April 2015

Somatic mutation frequencies (mutation burden) observed in “exomes” from 3,083 tumor–normal pairs.

Page 71: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

PD-1 Blockade in mCRC

N Eng J Med, Jun 2015

Page 72: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Prognosis

N Eng J Med, Jun 2015

Progression Free Survival for CRC Overall Survival for CRC

How about the efficacy of PD-1 blockade in other cancers with MRD?

Uterus, stomach, biliary tract, pancreas, ovary, prostate, and small intestine

Page 73: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Mutational Landscape of Melanoma according to the CTLA-4 blockade Response

Snyder A et al. N Engl J Med 2014;371:2189-2199.

Mutational Load

Survival in Discovery set

Page 74: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Nonsynonymous mutation burden associated with clinical benefit of anti–PD-1 therapy: NSCLC

Science 3 April 2015

Mutational burden vs Response

Mutational burden vs Prognosis

Smoking vs Prognosis

Page 75: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Mutation burden, clinical response, and factors contributing to mutation burden: NSCLC

Science 3 April 2015

Page 76: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Neoantigen burden & Intratumoral Heterogeneity (ITH)

Science MAR 2016

Page 77: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

다음 중 항 PD-1/PD-L1 저해제 치료로 가장 큰 임상적

이득이 가장 적을 것으로 예상되는 환자는?

1) Luminal A type 골전이만 있는 32세 유방암 환자

2) Lynch syndrome으로 진단받은 43세 전이성 대장암 환자

3) 흡연력이 있는 56세 4기 폐편평상피세포암 환자

4) BRCA1 돌연변이가 있는 36세 전이성 삼중음성 유방암 환자

5) 50갑년의 흡연력이 있는 72세 전이성 방광암 환자

Page 78: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Nanda et al, 2014 SABCS

Monotherapy might not be enough!

Page 79: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Rational Application of Immunotherapeutics

• Biomarkers

- PD-1/PD-L1 expression

- Mutational load

• Combination strategy

• Immune monitoring

Page 80: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Therapeutic Strategies to Harness Immune System

Page 81: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Combination of anti-CTLA4/anti-PD-1 in Untreated Melanoma

Postow MA et al. N Engl J Med 2015;372:2006-2017.

Page 82: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Rational Application of Immunotherapeutics

• Biomarkers

- PD-1/PD-L1 expression

- Mutational load

• Combination strategy

• Immune monitoring

Page 83: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Strategies for Immune Monitoring

Annu. Rev. Med. 2014.65:185-202

Page 84: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

CD8+ T cells with Pembrolizumab

Nature 515, 568–571 (27 November 2014)

Response (n=22)

Progression (n=24)

Page 85: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Proliferating CD8+ T cells in Regressing Tumors

Nature 515, 568–571 (27 November 2014)

Page 86: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Anything in blood? - Immune cell profiles - Cytokines - PBMC Immunomics

Page 87: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Baseline serum Cytokine score impacts OS in NSCLC

• Explorative analysis of CM-063 and 017

• SQ-Cytoscore: IL-6, FRTN, CRP, MIP-16, Ip-10, IL-16, MICA, IL-1RA, MMP3, MIG, ICAM1, VDBP, vWF

2016 ASCO

Page 88: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Personalized Immunotherapy Strategy

Briefings in Bioinformatics, 2015, 1–15

Optimized Immunotherapy Protocol Computational

Immunotherapy : Vaccine etc

Immune Monitoring

Patient Profiling

Page 89: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Future Oncology Treatment Paradigm…

89

Biomarkers supported by - Genomics - Seromics - Immunomics

Personalized, Combined, Immunotherapy

Page 90: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Summary & Future…

• Immunotherapy changed the paradigm of cancer therapy.

• CTLA-4 opened the door to age of immunotherapeutics for cancer.

• PD-1/PD-L1 antibodies harnessed new cancers to immunogenic ones.

• Identification of combinatorial strategy is a future direction.

• Development of predictive biomarkers is ongoing.

• More Understanding about tumor biology.

• Characterizing tumor immune microenvironment according to types and stages of tumors.

• Rational application of ‘omics’ for personalized approach.

Page 91: Basics of Immuno-OncologyAACR Cancer Progress Report 2014 Phase III Trial: Ipilimumab/gp100 vs Ipilimumab vs gp100 OS Ipilimumab/gp100 (n=403) Ipilimumab (n=137) Gp100 (n=136) mOS

Research Cures Cancer!